Sign In
Buy SLP
$18.15
+0.0500 (+0.276%)
At Close: Jun 23, 2026
Simulations Plus Reports Successful Results from AIDD Collaboration with Large Pharmaceutical Company
08:30am, Wednesday, 07'th Apr 2021
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports excellent results from its Artificial Intelligence-driven Drug Design (AIDD) module in ADMET Predictor in testing by partner.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that its DILIsym division and the University of Pittsburgh Drug Discovery Institute jointly received a Phase I SBIR grant.
3 Top Healthcare Stocks That Can Make You Richer in 2021 (and Beyond)
06:36am, Wednesday, 17'th Feb 2021
What's better than rapid growth and a dividend payment?
Simulations Plus to Participate in BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
08:30am, Thursday, 11'th Feb 2021
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host fireside chat at BTIG's Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 18, at 12pm ET.
Simulations Plus: Niche Market Leader With Strong Balance Sheet
07:56pm, Friday, 05'th Feb 2021
The modelling and simulation software market for drug discovery and development is niche and IP-intensive, with high barriers to entry. Simulations Plus has a good track record and strong balance shee
Simulations Plus (SLP) Stock Down Despite Q1 Earnings Beat
11:17am, Wednesday, 13'th Jan 2021
Simulations Plus (SLP) fiscal first-quarter results reflect solid software and service revenue growth. However, coronavirus crisis affected renewals.
Simulations Plus Keeps Up Its Momentum in the New Fiscal Year
11:15am, Wednesday, 13'th Jan 2021
The company continues to anticipate swift, double-digit revenue growth over the next several quarters.
New York, New York--(Newsfile Corp. - January 12, 2021) - Levi & Korsinsky announces it has commenced an investigation of Simulations Plus, Inc. (NASDAQ: SLP) concerning possible breaches of fiducia
Simulations Plus to Present at 23rd Annual Needham Virtual Growth Conference
08:45am, Tuesday, 12'th Jan 2021
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that CEO Shawn O'Connor will present at the 23rd Annual Needham Virtual Growth Conference on January 14, 2021, at 2pm ET.
Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2021 Results - Earnings Call Transcript
11:08pm, Monday, 11'th Jan 2021
Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q1 2021 Results - Earnings Call Transcript
Simulations Plus (SLP) Q1 Earnings and Revenues Top Estimates
06:03pm, Monday, 11'th Jan 2021
Simulations Plus (SLP) delivered earnings and revenue surprises of 9.09% and 1.35%, respectively, for the quarter ended November 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Simulations Plus Q1 Earnings
05:11pm, Monday, 11'th Jan 2021
Shares of Simulations Plus (NASDAQ:SLP) were flat after the company reported Q1 results. Quarterly Results Earnings per share increased 9.09% year over year to $0.12, which beat the estimate of $0.11.
Earnings Outlook For Simulations Plus
10:07am, Friday, 08'th Jan 2021
Simulations Plus (NASDAQ:SLP) releases its next round of earnings this Monday, January 11. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.
Simulations Plus (SLP) to Post Q1 Earnings: What's in Store?
12:02pm, Wednesday, 06'th Jan 2021
Simulations Plus (SLP) fiscal first-quarter results are likely to reflect gains from solid uptick in modeling and simulations workflow platform for drug development across pharma and biotech industrie
3 Skyrocketed Software Stocks That Might Lose Sheen in 2021
10:32am, Monday, 21'st Dec 2020
We discuss three software stocks -- COUP, NUAN and SLP -- which might not sustain market beating run in 2021, owing to persistent macroeconomic weakness across SMBs induced by coronavirus outbreak.
